短效胰島素市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物、應用、地區和競爭對手分類，2021-2031年

全球短效胰島素市場預計將從 2025 年的 81.6 億美元成長到 2031 年的 104.9 億美元，複合年成長率為 4.27%。

此類治療方案是一種重要的餐前荷爾蒙替代療法，旨在模擬餐後人體自然分泌的胰島素，從而調節血糖值。推動這一領域發展的主要因素是全球糖尿病盛行率和肥胖率的上升，這兩者都需要有效的血糖控制來預防嚴重的健康併發症。根據國際糖尿病聯盟（IDF）預測，到2024年，全球20至79歲的糖尿病患者將達到約5.89億，這意味著不斷成長的患者群體對可靠的治療性介入的需求將持續而迫切。

然而，胰島素生產高成本以及產品核可的嚴格監管要求嚴重阻礙了市場擴張。這些經濟和法律障礙往往造成患者在取得和負擔能力方面的不平等，尤其是在醫療資源有限的中低收入地區。這些挑戰有效地限制了這些關鍵治療方法的普及，並對主要成長市場的患者依從性產生負面影響，阻礙了該行業充分利用全球對糖尿病管理解決方案日益成長的需求。

市場促進因素

隨著原廠生物製劑專利陸續到期，經濟實惠的生物類似胰島素的引進和廣泛應用正在推動全球短效胰島素市場的變革。這項轉變將在已開發經濟體和對價格敏感的新興經濟體中引發激烈的價格競爭，從而擴大患者的用藥範圍。這將緩解醫療系統的財政壓力，同時加速先前因成本障礙而難以獲得治療的人群的用藥成長。百康生物製劑公司2024年10月發布的財報便是這項變革的成功例證。該財報顯示，其生物相似藥產品組合（包括其主要胰島素產品）的銷售額年增19%。這凸顯了價格親民的替代療法快速的市場滲透率和商業性可行性。

同時，胰島素輸注裝置和技術的進步透過提高給藥的準確性和便利性，進一步推動了市場成長。智慧胰島素筆和自動胰島素輸注（AID）系統的整合提高了患者的依從性和血糖控制效果，確保了對相容的速效胰島素製劑的穩定需求。這些技術綜效的影響在Inslet截至2024年11月的會計年度財務表現中得到了清晰體現，其銷售額成長了25.7%，達到5.439億美元，這主要得益於無導管胰島素幫浦的普及。此外，諾和諾德報告稱，2024年前九個月的胰島素產品銷售額成長了10%，反映了這些重要療法在全球的持續應用。

市場挑戰

全球短效胰島素市場面臨的主要阻礙因素是高昂的生產成本和嚴格的監管要求。胰島素產品的研發涉及複雜且資本密集的生物過程，必須嚴格遵守世界衛生組織制定的安全通訊協定和品質標準。這些嚴格的合規要求需要對專業設施和技術專長進行大量投資，從而為生產成本設定了較高的下限。這使得製造商無法在不損害財務永續性的前提下，大幅降低成本以在價格敏感的發展中地區擴大銷售。

因此，這些經濟和法律障礙直接限制了患者獲得治療的機會，並限制了關鍵成長地區的市場獲利能力。不斷上漲的零售價格超出了中低收入國家個人和醫療系統的負擔能力，導致治療資源不足。世界衛生組織（世衛組織）預測，到2024年，全球超過50%的糖尿病患者將無法獲得治療，而造成如此巨大差距的主要原因是低收入地區缺乏價格合理的胰島素和基本醫療保健服務。這場普遍存在的治療費用危機正在降低患者的留存率，並阻礙市場充分滿足日益成長的全球患者群體的需求。

市場趨勢

吸入式短效胰島素製劑的進步正在革新市場，為傳統的餐後注射提供了一種非侵入性的替代方案。這一趨勢旨在透過採用特殊顆粒工程技術的肺部給藥系統，實現與生理胰島素分泌相媲美的超快速吸收動力學，從而提高患者的生活品質和用藥依從性。這些創新製劑的商業性吸引力體現在Mankind公司截至2024年11月的會計年度財務表現中，其旗艦產品Afrezza的銷售額同比成長12%至1500萬美元，顯示糖尿病患者群體對無針治療方案的持續需求。

同時，轉向超速效胰島素類似物代表血糖管理領域的重大進步，旨在消除標準速效產品中存在的給藥與起效之間的時間延遲。透過使用新型輔料重新配製現有分子以加速吸收，製藥研發人員正在幫助患者在更接近餐前的時間給藥，從而改善餐後血糖控制。該產品類型在全球產品系列中繼續保持強勁的市場佔有率，諾和諾德公司報告稱，其超速效製劑Fiaspi在2024年第三季度的銷售額達到3.94億丹麥克朗，這證實了藥物動力學最佳化的胰島素在現代治療流程中仍然具有重要意義。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球短效胰島素市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 透過藥物（Apidra、Novolog、 Humalog、Novolin 等）
  • 依用途（1 型糖尿病、2 型糖尿病）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美短效胰島素市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲短效胰島素市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區短效胰島素市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲短效胰島素市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲短效胰島素市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球短效胰島素市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Novo Nordisk AS
• Sanofi SA
• Eli Lilly & Co
• Biocon Ltd
• Wockhardt Ltd
• Boehringer Ingelheim International GmbH
• Julphar Pharma Inc
• United Laboratories International Holdings Limited
• Tonghua Dongbao Pharmaceutical Co. Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Short-Acting Insulin Market is projected to expand from USD 8.16 billion in 2025 to USD 10.49 billion by 2031, achieving a compound annual growth rate of 4.27%. This therapeutic category functions as a vital prandial hormone replacement, designed to regulate blood glucose levels by mimicking the body's natural insulin release immediately following food ingestion. The primary catalyst for this growth is the escalating global incidence of diabetes mellitus alongside rising obesity rates, both of which necessitate effective glycemic control to prevent severe health complications. According to the International Diabetes Federation, approximately 589 million adults aged 20 to 79 were living with diabetes worldwide in 2024, creating an urgent and sustained demand for reliable therapeutic interventions across an expanding patient demographic.

However, market expansion is significantly impeded by the high costs associated with insulin manufacturing and the stringent regulatory requirements necessary for product approval. These economic and legislative hurdles often create disparities in access and affordability, particularly within low-to-middle-income regions where healthcare resources are limited. Such challenges effectively restrict the widespread adoption of these critical treatments and negatively impact patient adherence rates in key growth markets, preventing the sector from fully capitalizing on the rising global need for diabetes management solutions.

Market Driver

The introduction and adoption of cost-effective biosimilar insulins act as a transformative driver for the Global Short-Acting Insulin Market, particularly as patents for originator biologics expire. This transition fosters intense price competition and broadens patient access in both developed nations and price-sensitive emerging economies, alleviating financial pressure on healthcare systems while accelerating volume uptake among populations previously constrained by cost barriers. The success of this shift is highlighted by Biocon Biologics, which reported a 19% year-over-year revenue increase in its biosimilars portfolio, including key insulin assets, in its October 2024 earnings update, underscoring the rapid market penetration and commercial viability of these affordable therapeutic alternatives.

Concurrently, advancements in insulin delivery devices and technology are further propelling market growth by enhancing the precision and convenience of administration. The integration of smart insulin pens and automated insulin delivery (AID) systems improves patient adherence and glycemic outcomes, thereby securing consistent demand for compatible fast-acting insulin formulations. The impact of this technological synergy is evident in Insulet Corporation's November 2024 financial results, where revenue surged by 25.7% to $543.9 million driven largely by tubeless pump adoption. Additionally, Novo Nordisk reported a 10% growth in insulin product sales during the first nine months of 2024, reflecting sustained global usage of these essential therapeutics.

Market Challenge

A substantial restraint on the global short-acting insulin market is the prohibitive cost of manufacturing combined with stringent regulatory requirements. Developing insulin products involves complex, capital-intensive biological processes that must strictly adhere to safety protocols and quality standards established by international health authorities. These rigorous compliance obligations necessitate significant investment in specialized facilities and technical expertise, creating a high production price floor that prevents manufacturers from aggressively lowering costs to capture volume in price-sensitive developing regions without compromising their financial sustainability.

Consequently, these economic and legislative barriers directly limit patient access and restrict the market's revenue potential in critical growth territories. High retail prices often exceed the financial capabilities of individuals and healthcare systems in low-to-middle-income countries, leading to suboptimal treatment uptake. According to the World Health Organization, more than 50% of people living with diabetes worldwide were not receiving treatment in 2024, a significant gap largely attributed to the lack of access to affordable insulin and essential care in lower-income settings. This widespread affordability crisis reduces patient adherence and prevents the market from fully serving the expanding global patient population.

Market Trends

Advancements in inhalable short-acting insulin solutions are driving a significant market shift by offering a non-invasive alternative to traditional prandial injections. This trend focuses on enhancing patient quality of life and compliance through pulmonary delivery systems that utilize specialized particle engineering to provide ultra-rapid absorption kinetics comparable to physiological insulin secretion. The commercial appeal of such innovative formulations is reflected in MannKind Corporation's November 2024 financial results, which reported a 12% year-over-year revenue increase for its flagship product, Afrezza, reaching $15 million and signaling a persistent demand for needle-free therapeutic options among the diabetes community.

Simultaneously, the transition toward ultra-rapid acting insulin analogs represents a critical evolution in glycemic management, aiming to close the time lag between administration and the onset of action found in standard rapid-acting products. By reformulating existing molecules with novel excipients to accelerate absorption, pharmaceutical developers allow patients to administer dosage closer to mealtime for improved postprandial glucose control. This product class continues to maintain a strong footprint in global portfolios, as evidenced by Novo Nordisk's report of 394 million Danish kroner in sales for its ultra-rapid formulation Fiasp during the third quarter of 2024, underscoring the sustained relevance of pharmacokinetically optimized insulins in modern treatment algorithms.

Key Market Players

• Novo Nordisk AS
• Sanofi SA
• Eli Lilly & Co
• Biocon Ltd
• Wockhardt Ltd
• Boehringer Ingelheim International GmbH
• Julphar Pharma Inc
• United Laboratories International Holdings Limited
• Tonghua Dongbao Pharmaceutical Co. Ltd.

Report Scope

In this report, the Global Short-Acting Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Short-Acting Insulin Market, By Drugs

• Apidra
• Novolog
• Humalog
• Novolin
• Others

Short-Acting Insulin Market, By Application

• Type 1 Diabetes
• Type 2 Diabetes

Short-Acting Insulin Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Short-Acting Insulin Market.

Available Customizations:

Global Short-Acting Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Short-Acting Insulin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drugs (Apidra, Novolog, Humalog, Novolin, Others)
  • 5.2.2. By Application (Type 1 Diabetes, Type 2 Diabetes)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Short-Acting Insulin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drugs
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Short-Acting Insulin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drugs
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Short-Acting Insulin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drugs
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Short-Acting Insulin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drugs
      • 6.3.3.2.2. By Application

7. Europe Short-Acting Insulin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drugs
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Short-Acting Insulin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drugs
      • 7.3.1.2.2. By Application
  • 7.3.2. France Short-Acting Insulin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drugs
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Short-Acting Insulin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drugs
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Short-Acting Insulin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drugs
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Short-Acting Insulin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drugs
      • 7.3.5.2.2. By Application

8. Asia Pacific Short-Acting Insulin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drugs
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Short-Acting Insulin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drugs
      • 8.3.1.2.2. By Application
  • 8.3.2. India Short-Acting Insulin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drugs
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Short-Acting Insulin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drugs
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Short-Acting Insulin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drugs
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Short-Acting Insulin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drugs
      • 8.3.5.2.2. By Application

9. Middle East & Africa Short-Acting Insulin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drugs
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Short-Acting Insulin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drugs
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Short-Acting Insulin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drugs
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Short-Acting Insulin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drugs
      • 9.3.3.2.2. By Application

10. South America Short-Acting Insulin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drugs
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Short-Acting Insulin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drugs
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Short-Acting Insulin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drugs
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Short-Acting Insulin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drugs
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Short-Acting Insulin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novo Nordisk AS
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi SA
• 15.3. Eli Lilly & Co
• 15.4. Biocon Ltd
• 15.5. Wockhardt Ltd
• 15.6. Boehringer Ingelheim International GmbH
• 15.7. Julphar Pharma Inc
• 15.8. United Laboratories International Holdings Limited
• 15.9. Tonghua Dongbao Pharmaceutical Co. Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer